Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Humanized mouse models for siRNA, ASO, AOC, AAV and CAR-T evaluation — with target, effector and PK humanization
Species differences can make conventional animal models uninformative for human-specific molecules: an siRNA or ASO designed against a human sequence may find no fully complementary target transcript, and a human CAR may not recognize a murine antigen. We provide humanized mouse models and integrated in vivo pharmacology services to enable the evaluation of oligonucleotide therapeutics and cell and gene therapeutics (CGT)—from target engagement to functional and pharmacological readouts.
Before entering clinical development, oligonucleotide therapeutics and CGT products require in vivo evaluation of therapeutic activity, target modulation, tissue distribution, and pharmacological responses.
Whether these data are interpretable depends on one condition: the animal model must reproduce the molecular interactions required by the MOA of the candidate drug. When it does not, efficacy, dose-response and target engagement readouts can be limited or misleading, regardless of how carefully species differences are noted in analysis.
The failure mode differs by therapeutic modality and mechanism of action.
Oligonucleotide Therapeutics
Cell and Gene Therapeutics (CGT)
The Key Challenge
A suitable preclinical model must reproduce the biological components required for the candidate drug to engage its target and generate interpretable pharmacological responses.
Humanized animal models help overcome some of the species-related constraints by incorporating relevant human biological components in an animal background. Depending on the research purposes, these can be therapeutic targets in humans, receptors for delivery, disease-associated genes or immune components.
Instead of applying humanization as a universal approach, we select model configurations based on the target specificity, mechanism of action, delivery requirements and intended pharmacological endpoints of the candidate drug. Each project starts with a model strategy proposal specifying the humanization approach, control groups, readouts and decision points.
Our Model Development and Pharmacology Capabilities
Target-Specific Model Solutions
Model selection and development across cardiometabolic, adipose, neuromuscular, CNS, and immuno-oncology research areas.
Model Characterization
Assessment of human target expression, tissue distribution, and relevant biological functions.
Integrated Pharmacology Support
In vivo efficacy evaluation, target modulation, tissue analysis, and PK/PD assessment where applicable.
We support model selection and in vivo pharmacology evaluation across two major therapeutic categories.
| Target | Therapeutic Application | Recommended Humanized Configuration | Key Readouts |
|---|---|---|---|
| LPA | Elevated Lp(a); cardiovascular risk | Human LPA transgenic model; additional human APOB background if required | Plasma Lp(a), apo(a) protein, LPA mRNA suppression |
| INHBE | Obesity; fat-selective weight management | Humanized INHBE knock-in; optional combination with humanized ALK7 | Hepatic INHBE mRNA, circulating Activin E, body weight, fat and lean mass |
| ALK7 / ACVR1C | Obesity; adipose tissue regulation | Humanized ALK7 knock-in model | Adipose hALK7 mRNA knockdown, body composition, metabolic parameters |
| PCSK9 | Hypercholesterolemia; LDL-C reduction | Humanized PCSK9 model; conventional model only when candidate cross-reactivity is confirmed and scientifically justified. | Plasma PCSK9, LDL-C, total cholesterol |
| APOC3 | Hypertriglyceridemia; dyslipidemia | Human APOC3 transgenic/humanized model; conventional model only when candidate cross-reactivity is confirmed and scientifically justified. | Plasma APOC3, triglycerides, lipid profile |
| ANGPTL3 | Dyslipidemia; triglyceride and LDL-C regulation | Humanized ANGPTL3 model; conventional model only when candidate cross-reactivity is confirmed and scientifically justified. | Plasma ANGPTL3, triglycerides, LDL-C, lipid profile |
| Target / Biological Component | Therapeutic Application | Recommended Humanized Configuration | Key Readouts |
|---|---|---|---|
| TFR1 + DMPK | DM1; muscle-targeted oligonucleotide delivery | Humanized TfR1 combined with DMSXL human DMPK disease model | Muscle mutant DMPK RNA, RNA foci, alternative splicing correction |
| PRNP / PrP | Prion diseases; CNS-targeted oligonucleotide therapeutics | Human PRNP transgenic or humanized mouse model | Brain and spinal cord PrP mRNA/protein, tissue distribution, disease-associated endpoints |
| Target | Therapeutic Application | Recommended Humanized Configuration | Key Readouts |
|---|---|---|---|
| CD19 | In vivo CAR-T for B-cell malignancies | HSC-humanized immune system with human T- and B-cell compartments; CD19-positive tumor model where required | CAR-positive human T-cell frequency, B-cell depletion, tumor burden, human cytokines |
| BCMA | CAR-T for multiple myeloma | BCMA-positive myeloma xenograft; PBMC- or HSC-humanized background according to study objectives | Tumor burden, CAR-T expansion and persistence, BCMA expression, cytokine profiles |
| CLDN18.2 | CAR-T for gastric and pancreatic cancers | Cross-reactive mouse target model with CLDN18.2-positive tumor models; humanized target model if needed | Tumor growth inhibition, CAR-T infiltration, gastric tissue injury, on-target/off-tumor effects |
| GPC3 | CAR-T for hepatocellular carcinoma | GPC3-positive tumor xenograft; humanized target model where required | Tumor burden, CAR-T infiltration, target expression, survival |
| MSLN | CAR-T for mesothelin-positive solid tumors | MSLN-positive tumor xenograft; humanized target model where required | Tumor burden, CAR-T expansion, target expression, normal tissue effects |
| Model Platform | Therapeutic Application | Model Configuration | Key Readouts |
|---|---|---|---|
| PBMC-Humanized Model | CAR-T and TCE efficacy evaluation | Human PBMC-engrafted immunodeficient mice, combined with antigen-positive tumor models where appropriate | Human T-cell activation and expansion, CAR-T activity, tumor growth inhibition, cytokine release |
| HSC-Humanized Model | In vivo CAR-T generation and immune system-related evaluation | Human HSC-engrafted mice with reconstituted human immune cell compartments; tumor models where required | Human T-cell development, CAR-positive cell frequency, B-cell depletion, tumor burden, human cytokines |
Model configurations are selected according to drug-target compatibility, species cross-reactivity, and study objectives. Humanized target, immune system, and disease model components may be combined when required.
The appropriate humanization strategy depends on the drug's target specificity, mechanism of action, delivery route, and the biological context required for efficacy evaluation.
Endogenous Gene Humanization
Human target sequences are introduced into the corresponding mouse gene locus, enabling expression under endogenous regulatory elements.
Suitable for: Human-specific siRNA/ASO candidates, human receptors, and targets requiring physiologically regulated expression.
AAV-Mediated Human Gene Expression
AAV vectors deliver human target genes to selected tissues or cell populations to establish human gene expression in vivo.
Suitable for: Rapid proof-of-concept studies, selected tissue-specific targets, and disease-model combinations where stable germline humanization is not essential.
Multi-Component Humanization
Multiple human-specific components are incorporated into one model to address drug delivery, target recognition, and disease biology simultaneously.
Suitable for: Receptor-mediated oligonucleotide delivery, multi-target therapies, and complex pharmacological mechanisms.
Fc Receptor and FcRn Humanization
When a candidate depends on Fc-mediated effector function or FcRn-driven half-life extension, humanization extends beyond the target to Fc receptors and FcRn. Model configurations include hFcγR humanized mice for in vivo effector-function ranking, hFcRn humanized mice for FcRn-dependent PK, and hFcRn × immunodeficient backgrounds to separate FcRn effects from ADA interference.
Suitable for: Fc-engineered antibodies, Fc-containing CAR constructs, T-cell engagers, and antibody-oligonucleotide conjugates (AOC).

Humanized models are characterized beyond gene expression to confirm target expression, biological function, and pharmacological relevance.
Characterization strategies are tailored to the target, model configuration, and therapeutic modality to support reliable in vivo pharmacology evaluation.
Model preparation
PK/PD and tissue analysis
Target assessment and strategy proposal
Efficacy study design and execution
IND-enabling reporting
When is a humanized animal model necessary for small nucleic acid drug evaluation?
A humanized model may be required when a candidate siRNA or ASO specifically recognizes the human target sequence but has low activity against the corresponding mouse gene. If the candidate has adequate activity against the animal target, a conventional model may be sufficient, depending on the study objective.
What is the difference between an AAV-mediated model and a gene-humanized model?
Gene-humanized models replace the endogenous mouse locus with human sequences, preserving native regulatory control. AAV-mediated models deliver human genes episomally, which can be faster but may not replicate physiological expression or regulation.
Can one humanized model be used for both efficacy and safety evaluation?
Not always. A model that is appropriate for assessing target knockdown or antitumor efficacy may not recapitulate human immune interactions or normal-tissue toxicity. Each pharmacological or safety question should be evaluated separately for model suitability.
How do you evaluate whether a humanized model is pharmacologically relevant?
Evaluation may include: human-specific mRNA and protein expression, tissue distribution, functional target recognition, downstream pathway activity, and response to reference compounds or therapeutic candidates.
Share your target, therapeutic modality, and study objectives with our team to explore suitable model strategies and in vivo evaluation plans.